105 related articles for article (PubMed ID: 34818014)
1. Stapled Peptides Targeting SARS-CoV-2 Spike Protein HR1 Inhibit the Fusion of Virus to Its Cell Receptor.
Zheng M; Cong W; Peng H; Qing J; Shen H; Tang Y; Geng C; Chen S; Zou Y; Zhang WD; Hu HG; Li X
J Med Chem; 2021 Dec; 64(23):17486-17495. PubMed ID: 34818014
[TBL] [Abstract][Full Text] [Related]
2. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
3. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
Bi W; Chen G; Dang B
J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
[TBL] [Abstract][Full Text] [Related]
4. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
[TBL] [Abstract][Full Text] [Related]
5. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein.
Yang K; Wang C; Kreutzberger AJB; Ojha R; Kuivanen S; Couoh-Cardel S; Muratcioglu S; Eisen TJ; White KI; Held RG; Subramanian S; Marcus K; Pfuetzner RA; Esquivies L; Doyle CA; Kuriyan J; Vapalahti O; Balistreri G; Kirchhausen T; Brunger AT
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2210990119. PubMed ID: 36122200
[TBL] [Abstract][Full Text] [Related]
6. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein.
Yang K; Wang C; Kreutzberger AJB; Ojha R; Kuivanen S; Couoh-Cardel S; Muratcioglu S; Eisen TJ; White KI; Held RG; Subramanian S; Marcus K; Pfuetzner RA; Esquivies L; Doyle CA; Kuriyan J; Vapalahti O; Balistreri G; Kirchhausen T; Brunger AT
bioRxiv; 2022 Aug; ():. PubMed ID: 35982670
[TBL] [Abstract][Full Text] [Related]
7. Designing Self-Inhibitory fusion peptide analogous to viral spike protein against novel severe acute respiratory syndrome (SARS-CoV-2).
Singh I; Singh S; Ojha KK; Yadav NS
J Biomol Struct Dyn; 2022; 40(21):11357-11372. PubMed ID: 34379031
[TBL] [Abstract][Full Text] [Related]
8. Repurposing fusion inhibitor peptide against SARS-CoV-2.
Efaz FM; Islam S; Talukder SA; Akter S; Tashrif MZ; Ali MA; Sufian MA; Parves MR; Islam MJ; Halim MA
J Comput Chem; 2021 Dec; 42(32):2283-2293. PubMed ID: 34591335
[TBL] [Abstract][Full Text] [Related]
9. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.
Bosch BJ; van der Zee R; de Haan CA; Rottier PJ
J Virol; 2003 Aug; 77(16):8801-11. PubMed ID: 12885899
[TBL] [Abstract][Full Text] [Related]
10. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein.
Fan X; Cao D; Kong L; Zhang X
Nat Commun; 2020 Jul; 11(1):3618. PubMed ID: 32681106
[TBL] [Abstract][Full Text] [Related]
11. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
Ni L; Zhu J; Zhang J; Yan M; Gao GF; Tien P
Biochem Biophys Res Commun; 2005 Apr; 330(1):39-45. PubMed ID: 15781229
[TBL] [Abstract][Full Text] [Related]
12. Investigating vulnerability of the conserved SARS-CoV-2 spike's heptad repeat 2 as target for fusion inhibitors using chimeric miniproteins.
Polo-Megías D; Cano-Muñoz M; Berruezo AG; Laumond G; Moog C; Conejero-Lara F
Int J Biol Macromol; 2024 Mar; 262(Pt 2):130132. PubMed ID: 38354919
[TBL] [Abstract][Full Text] [Related]
13. Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins.
Polo-Megías D; Cano-Muñoz M; Berruezo AG; Laumond G; Moog C; Conejero-Lara F
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555153
[TBL] [Abstract][Full Text] [Related]
14. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.
Xia S; Yan L; Xu W; Agrawal AS; Algaissi A; Tseng CK; Wang Q; Du L; Tan W; Wilson IA; Jiang S; Yang B; Lu L
Sci Adv; 2019 Apr; 5(4):eaav4580. PubMed ID: 30989115
[TBL] [Abstract][Full Text] [Related]
15. Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4.
Xia S; Lan Q; Pu J; Wang C; Liu Z; Xu W; Wang Q; Liu H; Jiang S; Lu L
Viruses; 2019 Jan; 11(1):. PubMed ID: 30646495
[TBL] [Abstract][Full Text] [Related]
16. Targeting the SARS-CoV-2 HR1 with Small Molecules as Inhibitors of the Fusion Process.
Gentile D; Coco A; Patamia V; Zagni C; Floresta G; Rescifina A
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077465
[TBL] [Abstract][Full Text] [Related]
17. Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit.
Kandeel M; Yamamoto M; Tani H; Kobayashi A; Gohda J; Kawaguchi Y; Park BK; Kwon HJ; Inoue JI; Alkattan A
Biomol Ther (Seoul); 2021 May; 29(3):282-289. PubMed ID: 33424013
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus.
Sun Y; Zhang H; Shi J; Zhang Z; Gong R
Viruses; 2017 Sep; 9(9):. PubMed ID: 28906430
[TBL] [Abstract][Full Text] [Related]
19. Dimerized fusion inhibitor peptides targeting the HR1-HR2 interaction of SARS-CoV-2.
Tsuji K; Baffour-Awuah Owusu K; Miura Y; Ishii T; Shinohara K; Kobayakawa T; Emi A; Nakano T; Suzuki Y; Tamamura H
RSC Adv; 2023 Mar; 13(13):8779-8793. PubMed ID: 36950081
[TBL] [Abstract][Full Text] [Related]
20. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus.
Gao J; Lu G; Qi J; Li Y; Wu Y; Deng Y; Geng H; Li H; Wang Q; Xiao H; Tan W; Yan J; Gao GF
J Virol; 2013 Dec; 87(24):13134-40. PubMed ID: 24067982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
